Jakafi receives FDA approval for treatment of chronic GVHD

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Jakafi (ruxolitinib) has received FDA approval for treatment of chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login